In the quarter, revenue was at Rs1,207cr up by 30.2% yoy. Also, the EBITDA surged by 84% yoy to Rs327.52cr in the period.
Meanwhile, EBITDA margin improved to 27.13% in Q4 against19.2% in the same period previous fiscal.
In its financial audit report, Alembic revealed that exceptional items relate to impairment provision on investment in and loan given to Joint Venture namely Alembic Marni Algeria held by a wholly-owned subsidiary of the company Rs69.06cr, compensation to National Green Tribunal Rs10cr and write back of certain provisions, refund by the vendor for non-performance and settlement of Rs35.42cr.
The company's board declared Interim Dividend of Rs7(350%) per equity share and an additional Special Dividend of Rs3 (150%) per equity share on March 06, aggregating to total Interim Dividend of Rs10 (500%) per equity share having face value of Rs2 each for FY20. The same has been paid on March 20, 2020, to the equity shareholders of the Company.
For FY20, Alembic's net profit and revenue came in at Rs 828.82cr and Rs4,605.75cr up by 41.8% and 17.1% yoy.
On Sensex, the Alembic Pharma stock price ended at Rs897.50 per piece flat compared to the previous closing of Rs897.65 per piece.